Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer reports positive breast cancer efficacy data for Ibrance

Pfizer reports positive breast cancer efficacy data for Ibrance

18th November 2016

Pfizer has announced the publication of phase III clinical trial data that demonstrates the benefits of its drug Ibrance in the treatment of breast cancer.

Results from the phase III PALOMA-2 trial have been published in the New England Journal of Medicine showing the effectiveness of Ibrance as an initial therapy for postmenopausal women with oestrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer.

A combination of Ibrance and letrozole was shown to extend progression-free survival by more than ten months compared with letrozole plus placebo, with the median progression-free survival rate exceeding two years.

This makes Ibrance the first and only treatment for this population of women to achieve this benefit in a randomised phase III study.

Dr Mace Rothenberg, chief development officer for oncology at Pfizer Global Product Development, said: "We look forward to sharing the full PALOMA-2 data with global regulatory authorities with the goal of making Ibrance available to more women around the world."

Since its US approval in February 2015, over 40,000 women have been prescribed Ibrance by more than 8,500 prescribers. The therapy has also been ratified by the European Commission.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801828580-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.